Edition:
United States

Ionis Pharmaceuticals Inc (IONS.O)

IONS.O on Nasdaq

72.99USD
18 Apr 2019
Change (% chg)

$0.32 (+0.44%)
Prev Close
$72.67
Open
$72.53
Day's High
$74.00
Day's Low
$70.87
Volume
2,181,791
Avg. Vol
1,053,217
52-wk High
$86.58
52-wk Low
$39.07

About

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment,... (more)

Overall

Beta: 2.89
Market Cap(Mil.): $6,907.90
Shares Outstanding(Mil.): 124.35
Dividend: --
Yield (%): --

Financials

  IONS.O Industry Sector
P/E (TTM): 264.40 69.30 32.55
EPS (TTM): 0.21 -- --
ROI: 3.19 8.91 13.83
ROE: 15.59 10.06 15.25

EU committee approves Akcea-Ionis drug for rare genetic disease

March 1 An advisory committee of the European Medicines Agency (EMA) on Friday recommended conditionally approving a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals Inc that aims to treat a rare genetic disease that causes fat accumulation in the blood.

Mar 01 2019

Novartis aims to pump up cardio business with Ionis deal

ZURICH Novartis will pay $150 million to Ionis Pharmaceuticals to license an RNA-targeting cardiovascular drug as the Swiss company aims to bolster its range of heart disease treatments that now includes the blockbuster Entresto.

Feb 25 2019

UPDATE 2-Novartis aims to pump up cardio business with Ionis deal

* Novartis aims to build up heart drug portfolio (Adds comment from Novartis drug developer, details of payment and deal)

Feb 25 2019

BRIEF-Ionis Pharmaceuticals - Announced Partner Roche, also known as Genentech In U.S., enrolled first patient in study of Rg6042 for Huntington's disease

* IONIS PHARMACEUTICALS - ANNOUNCED PARTNER ROCHE, ALSO KNOWN AS GENENTECH IN U.S., ENROLLED FIRST PATIENT IN STUDY OF RG6042 FOR HUNTINGTON'S DISEASE

Jan 28 2019

Earnings vs. Estimates